Canaccord Genuity Reiterates Buy Rating, $18 PT on Derma Sciences

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating and $18.00 price target on Derma Sciences

. Canaccord noted, “We maintain our BUY rating following mixed Q2/12 results, with Y/Y revenue growth again driven by advanced wound care products while core products were soft due to weakness in the Canadian market. Management continues to execute on its AWC strategy, acquiring the rights to the Nimbus technology in the Q2/12. DSC127 is still on track for enrollment by YE/12.” Derma Sciences closed on Tuesday at $9.42.